Relation between lipids and atherosclerosis: epidemiologic evidence and clinical implications

Area of Science:

• Cardiovascular Medicine
• Epidemiology
• Pharmacology

Background:

• Coronary artery disease (CAD) is a primary cause of mortality globally.
• Established risk factors include dyslipidemia (abnormal cholesterol levels) and hypertension.
• Previous research identified adverse effects of high total and low-density lipoprotein cholesterol, and protective effects of high-density lipoprotein cholesterol.

Purpose of the Study:

• To review the established and emerging risk factors for coronary artery disease.
• To evaluate the impact of antihypertensive therapies on CAD morbidity and mortality.
• To explore newer pharmacological agents for CAD risk reduction.

Main Methods:

• Review of large-scale epidemiologic studies (e.g., Framingham Heart Study).
• Analysis of clinical trial data (e.g., Lipid Research Clinics Trial, Helsinki Heart Study).
• Examination of the metabolic effects of various antihypertensive drug classes.

Main Results:

• Lowering total cholesterol and increasing high-density lipoprotein cholesterol significantly reduce CAD risk.
• Diuretics and beta-blockers, despite lowering blood pressure, did not significantly decrease CAD morbidity or mortality.
• Adverse effects of traditional antihypertensives on lipid and glucose metabolism may explain their limited efficacy.

Conclusions:

• Traditional antihypertensives like diuretics and beta-blockers may not be optimal for reducing CAD risk due to metabolic side effects.
• Newer antihypertensive agents, such as ACE inhibitors and calcium channel blockers, show promise for CAD risk reduction.
• Further research is needed to confirm the cardiovascular benefits of newer antihypertensive classes.